Compare Inovio Pharmaceuticals Inc (INO) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Toyota Motor Corp trades at $185.3 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 1937.6× Inovio Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Toyota Motor Corp for 116 Days on average.
| INO | TM | |
|---|---|---|
Market Cap | $112.19M | $217.38B |
Volume | 3,201,278 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $248.29 |
52-Week Low | $0.66 | $166.50 |
Typical Hold Time | 43 Days | 116 Days |
Enterprise Value | $83.51M | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Toyota Motor (TM) trades at $186.00, up 1.69% today, with a bearish technical signal but strong fundamentals. The stock shows attractive valuation ratios, including a P/E of 8.38 and P/B of 0.93, and has beaten EPS estimates in recent quarters. Recent news highlights U.S. sales growth and electrification efforts, though production declines in China and floods in Thailand pose challenges. Cash flow turned negative in 2025 but is projected to rebound in 2026.
TM presents a value opportunity with low multiples and consistent profitability, but near-term headwinds from global sales softness and supply chain disruptions warrant caution. Analyst consensus is mixed, with 37.5% buy ratings versus 62.5% hold, reflecting balanced optimism and patience. The stock's outlook hinges on execution in electrification and recovery in key markets like China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
